Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of a New Branded Generic of Moxifloxacin Tablets
TCTR20201109001Phase 1Completed
- Sponsor
- N/A
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of moxifloxacin in bacterial disease (2 arms), sponsored by N/A. Primary endpoint: Primary pharmacokinetic bioequivalence. Started Dec 2017; status: completed.
02
Drugs
moxifloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on TCTR20201109001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201109001.